-
公开(公告)号:CA2713342A1
公开(公告)日:2009-08-13
申请号:CA2713342
申请日:2009-01-29
Applicant: ABBOTT LAB
Inventor: ARGIRIADI MARIA A , BORHANI DAVID W , XIANG TAO , WU CHENGBIN , GHAYUR TARIQ
IPC: A61K39/395
Abstract: The invention provides methods of crystallizing antibodies and fragments thereof as well as crystals produced thereby. More particularly, the invention provides methods of crystallizing human and non-human Fab fragments of antibodies, either alone or as co-crystals with their target ligand. For example, a crystal comprising a murine Fab fragment of the antibody 125-2H or a human Fab fragment of the antibody ABT-325, which bind to IL-18, are provided as well as a co-crystal of a murine Fab fragment bound to IL-18. ABT-325 and 125-2H differ significantly in combining site character and architecture, thus explaining their ability to bind IL-18 simultaneously at distinct epitopes.
-
公开(公告)号:BRPI0416255A
公开(公告)日:2007-01-09
申请号:BRPI0416255
申请日:2004-11-12
Applicant: ABBOTT LAB
Inventor: GHAYUR TARIQ , LABKOVSKY BORIS , VOSS JEFFREY W , GREEN LARRY , BABCOOK JOHN , JIA XIAO-CHI , WIELER JAMES , KANG JASPAL SINGH , HEDBERG BRAD
Abstract: The present invention encompasses IL-18 binding proteins, particularly antibodies that bind human interleukin-18 (hIL-18). Specifically, the invention relates to antibodies that are entirely human antibodies. Preferred antibodies have high affinity for hIL-18 and/or that neutralize hIL-18 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-18 and for inhibiting hIL-18 activity, e.g., in a human subject suffering from a disorder in which hIL-18 activity is detrimental.
-
公开(公告)号:NO20026239L
公开(公告)日:2003-02-27
申请号:NO20026239
申请日:2002-12-27
Applicant: ABBOTT LAB
Inventor: COLLINSON ALBERT , GHAYUR TARIQ , AVGERINOS GEORGE , DIXON RICHARD WOODWARD , KAYMAKCALAN ZEHRA
IPC: G01N33/50 , A61K39/395 , A61K47/48 , A61K49/00 , A61P1/04 , A61P17/06 , A61P25/00 , A61P29/00 , A61P37/06 , C07K16/24 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/09 , C12N15/13 , C12P21/08 , G01N33/15 , G01N33/53 , G01N33/68
Abstract: Antibodies having dual specificity for two different but structurally related antigens are provided. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or monoclonal antibodies. Preferred antibodies have dual specificity for IL-1 alpha and IL-1 beta and neutralize IL-1 alpha and IL-1 beta activity in vitro and in vivo. The antibody can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using these antibodies are also provided. These antibodies, or antibody portions, are useful for detecting two different but structurally related antigens (e.g., IL-1 alpha and IL-1 beta) and for inhibiting the activity of the antigens, (e.g., in a human subject suffering from a disorder in which IL-1 alpha and/or IL-1 beta activity is detrimental.
-
公开(公告)号:CY1112893T1
公开(公告)日:2016-04-13
申请号:CY121100602
申请日:2012-07-05
Applicant: ABBOTT LAB
Inventor: GHAYUR TARIQ , LABKOVSKY BORIS , VOSS JEFFREY W , GREEN LARRY , BABCOOK JOHN , JIA XIAO-CHI , WIELER JAMES , KANG JASPAL SINGH , HEDBERG BRAD
Abstract: Ηπαρούσαεφεύρεσηπεριλαμβάνει IL-18-δεσμευόμενεςπρωτεΐνες, ιδίωςαντισώματαπουδεσμεύονταιμεανθρώπινηιντερλευκίνη-18 (hIL-18). Συγκεκριμένα, ηεφεύρεσησχετίζεταιμεαντισώματαπουείναιεξολοκλήρουανθρώπινααντισώματα. Ταπροτιμητέααντισώματαέχουνυψηλήσυγγένειαγια hlL-18 και/ήεξουδετερώνουνδραστικότητα hIL-18 in vitro και in vivo. Αντίσωματηςεφεύρεσηςμπορείναείναιαντίσωμαπλήρουςμήκουςή τμήμααυτούπουδεσμεύεταιμεαντιγόνο. Παρέχεταιεπίσηςμέθοδοςπαρασκευήςκαιμέθοδοςχρήσηςτωναντισωμάτωντηςεφεύρεσης. Τααντισώματα, ήτμήματααντισωμάτων, τηςεφεύρεσηςείναιχρήσιμαγιαανίχνευση hIL-18 καιγιααναστολήδραστικότητας hIL-18, π.χ. σεάνθρωποπουυποφέρειαπόδιαταραχήστηνοποίαη δραστικότητα hIL-18 είναιεπιβλαβής.
-
公开(公告)号:BRPI0922807A2
公开(公告)日:2015-12-22
申请号:BRPI0922807
申请日:2009-12-04
Applicant: ABBOTT LAB
Inventor: WU CHENGBIN , JAKOB CLARISSA G , WALTER KARL A , GHAYUR TARIQ
-
公开(公告)号:BR112012002095A2
公开(公告)日:2015-09-01
申请号:BR112012002095
申请日:2010-07-29
Applicant: ABBOTT LAB
Inventor: GHAYUR TARIQ , LIU JUNJIAN , IBRAGHIMOV ALEXANDER
IPC: C12P21/08
-
公开(公告)号:CA2618482C
公开(公告)日:2014-10-07
申请号:CA2618482
申请日:2006-08-18
Applicant: ABBOTT LAB
Inventor: WU CHENGBIN , GHAYUR TARIQ , DIXON RICHARD W , SALFELD JOCHEN G
Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention and/or treatment of acute and chronic inflammatory and other diseases.
-
公开(公告)号:SG192489A1
公开(公告)日:2013-08-30
申请号:SG2013052725
申请日:2009-07-08
Applicant: ABBOTT LAB
Inventor: GHAYUR TARIQ , GU JIJIE , ISAKSON PETER C
Abstract: PROSTAGLANDIN E2 DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOFAbstractThe present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.Figure 1
-
公开(公告)号:SG191625A1
公开(公告)日:2013-07-31
申请号:SG2013041603
申请日:2009-06-03
Applicant: ABBOTT LAB
Inventor: GHAYUR TARIQ , HAHN ALFRED , MUELLER BERNHARD
Abstract: DUAL VARIABLE DOMAIN I MUNOGLOBULINS AND USES THEREOF Abstract 5 The present invention relates to engineered multivalent and multispecific bindingproteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.Figure I
-
公开(公告)号:MX2013004979A
公开(公告)日:2013-07-30
申请号:MX2013004979
申请日:2011-11-01
Applicant: ABBOTT LAB
Inventor: GHAYUR TARIQ , LIU JUNJIAN , GU JIJIE , HARRIS MARIA C
IPC: C12P21/08 , A61K39/395 , C07K16/00
Abstract: Se proporcionan proteínas de unión multivalentes y multiespecíficas diseñadas por ingeniería, métodos para elaborarlas y sus usos en la prevención, el diagnóstico y/o el tratamiento de enfermedades.
-
-
-
-
-
-
-
-
-